Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, 96 Week, Randomized, Partially Double-Blinded, Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of GW873140 in Combination With Combivir (Lamivudine and Zidovudine) Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults

Next Previous
X
Search
Trial Profile

A Phase IIb, 96 Week, Randomized, Partially Double-Blinded, Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of GW873140 in Combination With Combivir (Lamivudine and Zidovudine) Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aplaviroc (Primary) ; Efavirenz; Lamivudine/zidovudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ASCENT
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 31 Jul 2021 This trial has been completed in Spain according to European Clinical Trials Database record (Global end date: 23 July 2006).
    • 20 May 2009 Additional trial locations identified as reported by ClinicalTrials.gov.
    • 18 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top